Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 9
1946 35
1947 48
1948 56
1949 28
1950 1
1951 36
1952 93
1953 105
1954 92
1955 85
1956 89
1957 87
1958 79
1959 74
1960 72
1961 80
1962 62
1963 3
1964 7
1965 120
1966 202
1967 247
1968 274
1969 305
1970 305
1971 289
1972 345
1973 343
1974 337
1975 447
1976 364
1977 351
1978 367
1979 388
1980 379
1981 353
1982 362
1983 426
1984 449
1985 419
1986 451
1987 452
1988 543
1989 486
1990 571
1991 624
1992 711
1993 741
1994 801
1995 795
1996 800
1997 876
1998 859
1999 987
2000 1180
2001 1088
2002 1169
2003 1168
2004 1237
2005 1264
2006 1355
2007 1453
2008 1555
2009 1585
2010 1582
2011 1676
2012 1734
2013 1889
2014 1827
2015 1814
2016 1932
2017 1957
2018 1851
2019 703
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

44,876 results
Results by year
Filters applied: . Clear all
Page 1
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Kanner AM, et al. Neurology 2018. PMID 29898971
RESULTS: Several second-generation AEDs are effective for new-onset focal epilepsy. Data are lacking on efficacy in new-onset generalized tonic-clonic seizures, juvenile myoclonic epilepsy, or juvenile absence epilepsy, and on efficacy of third-generation AEDs in new-onset epilepsy. ...LTG should (Level B) and gabapentin (GBP) may (Level C) be considered in decreasing seizure frequency in patients ≥60 years of age with new-onset focal epilepsy. ...
RESULTS: Several second-generation AEDs are effective for new-onset focal epilepsy. Data are lacking on efficacy in new-onset general …
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Kanner AM, et al. Neurology 2018. PMID 29898974
RECOMMENDATIONS: The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment); rufinamide for Lennox-Gastaut syndrome (LGS) (add-on therapy). The following should be considered to decrease seizure frequency (Level B): lacosamide, eslicarbazepine, and extended-release topiramate for TRAFE (ezogabine production discontinued); immediate- and extended-release lamotrigine for generalized epilepsy with TR generalized tonic-clonic (GTC) seizures in adults; levetiracetam (add-on therapy) for TR childhood focal epilepsy (TRCFE) (1 month-16 years), TR GTC seizures, and TR juvenile myoclonic epilepsy; clobazam for LGS (add-on therapy); zonisamide for TRCFE (6-17 years); oxcarbazepine for TRCFE (1 month-4 years). ...
RECOMMENDATIONS: The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampan …
Epilepsy: Clinical Review and Surgical Options.
Karasin B and Karasin M. AORN J 2017 - Review. PMID 29107258
Epilepsy is the fourth leading neurologic disorder in the United States and affects the quality of life of approximately 2.9 million Americans. ...In the effort to optimize nursing care for patients with epilepsy, this article provides a clinical review of epilepsy as a neurologic disorder and specifically focuses on surgical interventions and perioperative nursing considerations....
Epilepsy is the fourth leading neurologic disorder in the United States and affects the quality of life of approximately 2.9 million
The problems facing epilepsy therapy.
Walker MC and Köhling R. Neuropharmacology 2013. PMID 23435169
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V and Perucca E. Drugs 2019 - Review. PMID 31372958
During the last 10 years, there has been increasing interest in the use of CBD-enriched products for the treatment of epilepsy. ...In four randomized, double-blind, parallel-group, adjunctive-therapy trials, CBD given at doses of 10 and 20 mg/kg/day administered in two divided administrations was found to be superior to placebo in reducing the frequency of drop seizures in patients with LGS and convulsive seizures in patients with DS. ...
During the last 10 years, there has been increasing interest in the use of CBD-enriched products for the treatment of epilepsy. ...In …
Epilepsy and music: practical notes.
Maguire M. Pract Neurol 2017 - Review. PMID 27903764
The idea that sound waves may directly affect brain waves has led researchers to explore music as therapy for epilepsy. There is limited and low quality evidence of an antiepileptic effect with the Mozart Sonata K.448. ...However, clinicians should consider musicality when treating patients with antiepileptic medication or preparing patients for epilepsy surgery. ...
The idea that sound waves may directly affect brain waves has led researchers to explore music as therapy for epilepsy. There …
Intractable Generalized Epilepsy: Therapeutic Approaches.
Hwang ST, et al. Curr Neurol Neurosci Rep 2019 - Review. PMID 30806817
PURPOSE OF REVIEW: To summarize recent developments in therapeutic options, both medical and surgical, for patients with drug-resistant generalized epilepsy syndromes, which continue to be a multifaceted challenge for patients and physicians. ...The current literature reflects a widening range of clinical experience with newer anticonvulsant medications including cannabinoids, dietary therapies, surgical approaches, and neurostimulation devices for patients with intractable generalized epilepsy....
PURPOSE OF REVIEW: To summarize recent developments in therapeutic options, both medical and surgical, for patients with drug-resistant gene …
The current and emerging therapeutic approaches in drug-resistant epilepsy management.
Mehdizadeh A, et al. Acta Neurol Belg 2019 - Review. PMID 30868468
However, 20-30% of epilepsy patients have seizure episodes that are not controlled by these medicines (drug-resistant epilepsy). ...An increasing number of novel and potential therapeutic approaches such as gene therapy, gene editing, cell therapy, exosome therapy, and molecular network targeting have also been explored. ...
However, 20-30% of epilepsy patients have seizure episodes that are not controlled by these medicines (drug-resistant epilepsy
44,876 results
Jump to page
Feedback